Neuraxis, Inc revenue
Neuraxis, Inc's revenue was $3.6m in fiscal 2025, up 32.9% on the year before. Since fiscal 2022 ($2.7m) it has grown at a compound 10.0% a year. Over the last twelve months it was $5.3m.
Revenue history
Where the revenue comes from
| Region | Revenue | Share | YoY |
|---|---|---|---|
| All Other States | $1.2M | 34.9% | ▲ 62.2% |
| Canada | $898,223 | 25.2% | ▲ 15.4% |
| OH | $578,769 | 16.2% | ▲ 34.2% |
| MA | $265,201 | 7.4% | ▲ 71.8% |
| Israel | $222,389 | 6.2% | ▼ 9.7% |
| WI | $215,431 | 6.0% | ▲ 36.5% |
| FL | $143,947 | 4.0% | ▼ 4.0% |
From Neuraxis, Inc's 10-K filed March 19, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Neuraxis, Inc | $5.3m | 65.2% | 25.6% |
| Lucid Diagnostics Inc. | $5.4m | 24.9% | 90.1% |
| Charming Medical Ltd | $4.8m | -22.7% | — |
| Bioaffinity Technologies, Inc. | $5.9m | -23.2% | -12.2% |
| Biomerica Inc | $4.3m | -11.2% | -7.1% |
| Intelligent BIO Solutions Inc. | $4.2m | 38.1% | 39.0% |
Compare with peers
- Lucid Diagnostics Inc. revenue
- Charming Medical Ltd revenue
- Bioaffinity Technologies, Inc. revenue
- Biomerica Inc revenue
- Intelligent BIO Solutions Inc. revenue
Head to head: LUCD vs NRXSMCTA vs NRXSBIAF vs NRXS
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies